Changes

Jump to navigation Jump to search

Stem cell statutes (view source)

Revision as of 04:55, April 26, 2023

343 bytes added ,  04:55, April 26, 2023
no edit summary
Line 3: Line 3:  
*21 U.S.C. § 331(k) (prohibiting the causing the misbranding of drugs)
 
*21 U.S.C. § 331(k) (prohibiting the causing the misbranding of drugs)
 
*21 U.S.C. § 331(c) (prohibiting the receipt of drugs that are misbranded)
 
*21 U.S.C. § 331(c) (prohibiting the receipt of drugs that are misbranded)
 +
 +
Some stem cell therapies are provided under laws providing for experimental treatment, which include:
 +
*21 U.S.C. § 355(b) or (j) (relating to approved new drug applications for the surgical treatments ("NDAs") filed with FDA) 
 +
*42 U.S.C. § 262 (relating to approved biologics license applications ("BLAs") filed with FDA for treatments)
 +
 
== See also ==
 
== See also ==
 
*[[Stem cell decisions]]
 
*[[Stem cell decisions]]
 
[[category:stem cells]]
 
[[category:stem cells]]
Aschlafly
Anthony, Irenaeus, Siteadmin, apieditor, Bureaucrats, Check users, nsAm_Govt_101RO, nsAm_Govt_101RW, nsAm_Govt_101_ta, nsJudgesRO, nsJudgesRW, nsJudges_talkRO, nsJudges_talkRW, nsTeam2RO, nsTeam2RW, nsTeam2_talkRO, nsTeam2_talkRW, oversight, Administrators
126,597

edits

Retrieved from "https://www.conservapedia.com/Special:MobileDiff/1943841"

Navigation menu